Paronychia and Periungual Granulation as a Novel Side Effect of Ibrutinib: A Case Report.

Abstract

Ibrutinib is an oral covalent inhibitor of the Bruton's tyrosine kinase pathway and is approved for the treatment of B-cell malignancies including chronic lymphocytic leukaemia, mantle cell lymphoma, and Waldenström's macroglobulinaemia. It is generally a drug of choice for high-risk patients with indolent lymphomas. The safety profile of ibrutinib appears to be tolerable, with well-known side effects such as infections and haematologic complications. Additionally, dermatological adverse reactions with ibrutinib therapy have been reported to encompass maculopapular rash and hair/nail abnormalities. Here, we present a case of ibrutinib-induced paronychia and periungual granulation in a 40-year-old woman. To the best of our knowledge, this is the third description of ibrutinib-induced paronychia and periungual granulation.

• Authors: Ahu Yorulmaz, Basak Yalcin
• Journal: Skin appendage disorders (Skin Appendage Disord) Vol. 6 Issue 1 Pg. 32-36 (Jan 2020) ISSN: 2296-9195 [Print] Switzerland
• PMID: 32021859 (Publication Type: Case Reports)
• Copyright: Copyright © 2019 by S. Karger AG, Basel.